Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (KB,vivo)

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2511-2520

  Van Steeg, T J ^a   Krekels, E H J ^a   Freijer, J ^b   Danhof, M ^a   De Lange, E C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

Author keywords

Alpha 1 acid glycoprotein; Free drug hypothesis; In vivo receptor affinity; Mechanism based; Pharmacokinetic pharmacodynamic models; Population pharmacokinetics pharmacodynamics; Protein binding; Receptors

Indexed keywords

ISOPRENALINE; METOPROLOL; OROSOMUCOID; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; HEART RATE; IN VITRO STUDY; MALE; NONHUMAN; PLASMA PROTEIN BINDING; RAT; RECEPTOR AFFINITY; TACHYCARDIA; WISTAR KYOTO RAT;

EID: 77951286918     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22014     Document Type: Article

References (34)

1. Wright JD, Boudinot FD, Ujhelyi MR. 1996. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30:445-462.
2. Pacifici GM, Viani A. 1992. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23:449-468.
3. Colmenarejo G. 2003. In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev 23:275-301.
4. Bergogne-Berezin E. 2002. Clinical role of protein binding of quinolones. Clin Pharmacokinet 41:741-750. (Pubitemid 34948195)
5. Rowland M, Tozer TN. 1995. Clinical pharmacokinetics - Concepts and applications. Philadelphia, PA: Williams & Wilkins.
6. Cox EH, Langemeijer MWE, Danhof M. 1998. Pharmacokinetic- pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials. J Pharmacol Toxicol Meth 39:19-27. (Pubitemid 28221555)
7. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, Mollmann C. 1993. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol 33:115-123.
8. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 257:472-478.
9. Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van Der Graaf PH, Peletier LA, Danhof M. 2003. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: In vitro-in vivo correlations. J Pharmacol Exp Ther 304:88-101.
10. Van Der Graaf PH, Van Schaick EA, Mathôt RA, Ijzerman AP, Danhof M. 1997. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: Estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816. (Pubitemid 27514643)
11. Johnsson G, Regardh CG. 1976. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233-263.
12. Mehvar R, Brocks DR. 2001. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 4:185-200. (Pubitemid 34305610)
13. Riddell JG, Harron DW, Shanks RG. 1987. Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. Clin Pharmacokinet 12:305-320.
14. Singh BN. 2005. Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: An overview. J Cardiovasc Pharmacol Ther 10:S3-S14.
15. Van Steeg TJ, Krekels EH, Danhof M, de Lange ECM. 2007. Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. J Pharmacol Toxicol Meth 56:72-78. (Pubitemid 46829932)
16. Van Steeg TJ, Freijer J, Danhof M, de Lange ECM. 2008. Mechanism-based pharmacodynamic modeling of S(-)-atenolol: Estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. J Pharmacol Exp Ther 324:1234-1242. (Pubitemid 351397831)
17. Van Steeg TJ, Boralli VB, Krekels EH, Slijkerman P, Freijer J, Danhof M, de Lange ECM. 2008. Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of b blockers using a new mechanism-based PK-PD modelling approach. J Pharm Sci December 30 [Epub ahead of print].
18. Breimer DD, Danhof M. 1997. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development-The 'Wooden Shoe' paradigm. Clin Pharmacokinet 32:259-267.
19. Van Der Graaf PH, Danhof M. 1997. Analysis of drug-receptor interactions in vivo: A new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 35:442-446. (Pubitemid 27462588)
20. Danhof M, de Jongh J, de Lange EC, Della PO, Ploeger BA, Voskuyl RA. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400. (Pubitemid 46272134)
21. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191.
22. Van Steeg TJ, Freijer J, Danhof M, de Lange ECM. 2007. Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: Reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. Br J Pharmacol 151: 356-366. (Pubitemid 46842675)
23. Kenakin TP. 1993. Pharmacologic analysis of drug-receptor interaction. New York: Lippincott Williams & Wilkins.
24. Black JW, Leff P. 1983. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
25. Doggrell SA, Petcu EB, Barnett CW. 1998. Affinity constants and beta-adrenoceptor reserves for isoprenaline on cardiac tissue from normotensive and hypertensive rats. J Pharm Pharmacol 50:215-223.
26. Terao N, Shen DD. 1983. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 227:369-375. (Pubitemid 14241128)
27. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R. 1985. Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1- acid glycoprotein. J Pharmacol Exp Ther 235:513-520. (Pubitemid 16248753)
28. Chindavijak B, Belpaire FM, De Smet F, Bogaert MG. 1988. Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat. J Pharmacol Exp Ther 246:1075-1079.
29. Belpaire FM, Bogaert MG. 1989. Pharmacokinetic and pharmacodynamic consequences of altered binding of drugs to alpha 1-acid glycoprotein. Prog Clin Biol Res 300:337-350.
30. Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT. 1986. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. Br J Pharmacol 88:697-705. (Pubitemid 16066937)
31. Chiu CC, Wu JR, Lee CH, Liou SF, Dai ZK, Chen IJ, Yeh JL. 2004. Anti-hypertension effect of vanylidilol: A phenylaldehyde alpha/beta- adrenoceptor blocker with endothelium-dependent and K+ channels opening-associated vasorelaxant activities. Pharmacology 70:140-151.
32. Juberg EN, Minneman KP, Abel PW. 1985. Beta 1- and beta 2- adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol 330:193-202.
33. Louis SN, Nero TL, Iakovidis D, Jackman GP, Louis WJ. 1999. LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol 367:431-435. (Pubitemid 29106398)
34. Nandakumar K, Bansal SK, Singh R, Bodhankar SL, Jindal DP, Coumar MS, Balaraman R, Bhardwaj SH. 2005. Selective beta(1)-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats. J Pharm Pharmacol 57:515-520. (Pubitemid 40515875)